Primary outcome
What NCT04466566 measured first
| Measure | Salinen=17 | Exendin-9, 39n=16 | Liraglutiden=16 |
|---|---|---|---|
| AG Genotype | 17(2) | 13(1) | 154(12) |
| AA Genotype | 33(3) | 58(23) | 542(143) |
| GG Genotype | 23(3) | 16(2) | 184(17) |
Phase 3 · Liraglutide
NCT04466566 trial results
Effect of Genetic Variation in the GLP-1 Receptor on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetic Humans
- Participants
- 21
- Status
- completed
- Completed
- 2025-12-30
- Sponsor
- Adrian Vella
As posted on ClinicalTrials.gov (NCT04466566), updated at source Oct 28, 2026. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
Side effects by arm
Side effects in NCT04466566
Percent of participants affected, Adverse events were collected from the time of informed consent through study completion, approximately 16 weeks.. The most common events the registry lists.
| Event | Saline | Exendin-9,39 | Liraglutide |
|---|---|---|---|
| Any serious event | 0% | 0% | 5.9% |
| Hypoglycemia | 0% | 5.9% | 17.6% |
| Nausea/Vomiting | 11.8% | 5.9% | 11.8% |
| Flushed/Hot/Diaphoretic | 5.9% | 5.9% | 11.8% |
| Headache | 11.8% | 0% | 5.9% |
| Asymptomatic hypoglycemia | 0% | 0% | 5.9% |
| Lightheaded/Shaky/Pale/Sweaty | 5.9% | 0% | 0% |
| Hypotension | 0% | 5.9% | 0% |
Secondary outcomes
What else it measured
| Measure | Salinen=17 | Exendin-9,39n=16 | Liraglutiden=16 |
|---|---|---|---|
| AG Genotype 0 Minutes | 20.6(5.5) | 22.8(4.6) | 22.1(3.4) |
| AA Genotype 0 Minutes | 36.4(7.9) | 57.7(15.3) | 46.0(6.4) |
| GG Genotype 0 Minutes | 18.7(1.3) | 19.3(2.5) | 17.2(1.9) |
| AG Genotype 180 Minutes | 5.8(0.1) | 6.4(0.6) | 6.3(0.1) |
| AA Genotype 180 Minutes | 6.6(0.1) | 6.5(0.1) | 6.3(0.1) |
| GG Genotype 180 Minutes | 6.1(0.1) | 6.0(0.1) | 6.0(0.2) |
The trial
How NCT04466566 was run
The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study to find out how genetic variations in GLP1R alter insulin secretion, in the fasting state and when blood sugars levels are elevated.
- Saline: Saline will be infused during the study
- Exendin-9,39: Exendin-9,39 will be infused during the study
- Liraglutide: Liraglutide will be infused during the study
Who could join the trial
Inclusion Criteria: * 40 nondiabetic subjects will be recruited. * 20 subjects with the AA or AG genotype at rs3765467 and remainder will have the GG genotype. * Individuals encompassing the age span of 18-65 years. Exclusion Criteria: * Individuals under 18 and over 65 years of age.
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.